Home
overview

SMi proudly presents the return of the 5th annual Cancer Vaccines conference to London in 2016. The use of cancer vaccines in combination with other cancer therapies is propelling the growth of the cancer vaccines market across the world. In addition factors such as the increasing number of people with cancer, rising public awareness of vaccines and the presence of promising late-stage pipeline candidate programs also enhance growth in the cancer vaccines market.*

The field of cancer vaccines is rapidly changing. Currently, different vaccination strategies such as conjugate-, DNA- and dendritic cell vaccines against tumor cells are being developed with increasing efficacy, SMi’s 5th annual Cancer Vaccines conference provides the perfect platform to delve further in to these strategies and engage in lively discussion within a concentrated and nice peer group.

A combination of cancer vaccines with pharmacotherapeutics remain the preferred choice to treat cancer. This not only increases the efficacy of the treatment but also helps improve the overall survival rate of patients.
SMi’s 5th annual Cancer Vaccines conference will heavily focus on the latest advances in combination therapies and personalised medicines.

The event will bring together leading industry professionals to discuss the immune checkpoint inhibitors and their use in vaccination, development and commercialisation of clinical trials and many more!
 

* http://www.fiercevaccines.com/press-releases/cancer-vaccines-market-growing-27-cagr-2019

 

  • Only European big pharma driven cancer vaccines event with pan European case studies
  • New topics for 2016 include personalised medicines & combination therapies
  • Special focus on commercialisation of cancer vaccines – to increase your speed to market
     

The following job titles in the field of cancer vaccine/immunology:

Head/Director/CEO

Director of Translational Research


Medical Scientist

Chief Medical Officer

Principal Scientist

R&D Project Leader

Chief Scientific Officer

Formulation Scientist

 

Activartis Biotech GmbH; Agalimmune Limited; ALmac Group; Amgen Limited; AstraZeneca; Avacta Life Sciences; Barts Cancer Institute; Bavarian Nordic G Mb H; Biosafe Sa; BIRD-C GmbH & CoKEG; Boehringer Ingelheim Pharma GmbH & Co. KG; Cancer Rearch UK; Cancer Research UK; Cancer Vaccines Ltd; DanDrit Biotech; Family Management Corporation; GP; Immunicum AB (publ); INSERM; IntelliCyt; IntelliCyt Corporation; Kings College London; National Cancer Institute; NHS Locum; Northwest Biotherapeutics; Northwest Biotherapeutics Inc; Nottingham Trent University; Ovacure; Plymouth University Peninsula Schools of Medicine and Dentistry, The Institute of Translational and Stratified Medicine; Rakvakcina Kft; Roche; Salamanca Group; Shionogi Limited; Solving Kids' Cancer; St Georges Hospital Medical School; St George's, University of London; Stanford University Cancer Institute; Statens Serum Institute; The John van Geest Cancer Research Centre; THERAVECTYS; Thomson Reuters; TRON Translational Oncology Mainz; UCB-Celltech; UCL Cancer Institute; UCLH BioResources; University Of Southampton; Vaccinogen;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Farzin Farzaneh

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London

9:10 Vaccination induced cellular immunity against cancer

Farzin Farzaneh

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London

• Survey of the most prominent immune therapy strategies –
including therapeutic antibodies, checkpoint blockades,
CAR T cells
• Whole cell vaccines – dendritic cells and gene modified
cancer cells
• New adjuvants for the induction of cellular immunity
• Combination of high throughput genomics, identification
of cancer specific neo-antigens, and new adjuvants for the
induction of therapeutic, cancer specific, cellular immunity

9:50 Biomarker strategies for cancer vaccine trials

Stephanie Traub

Stephanie Traub, Biomarker Development Specialist at the Centre for Drug Development , Cancer Research UK

• Case study: Biomarker strategies for dendritic cell vaccine
• Blood-based Biomarker correlation with tumour response
• Challenges of immune monitoring

10:30 Morning Coffee

11:00 Case Study: Reaching the optimal design for the ICT-107 phase III dendritic cell immunotherapy trial for treating newly diagnosed glioblastoma

Andrew Gengos

Andrew Gengos, President & CEO, ImmunoCellular Therapeutics Ltd

• Phase II trial results and immune monitoring insights
• Learnings and improvements identifi ed to optimise Phase III
design
• Phase III execution
 

11:40 Novel therapeutic dendritic-cell-targeting vaccine

Campbell Bunce

Campbell Bunce, SVP Scientific Operations, Abzena

• Case study: novel dendritic c-cell-targeting vaccine for the treatment of head and neck and cervical cancer
• Analysis of Phase I and Phase II clinical trials
• Composite CHOTM technology for the generation of stable cell lines

12:20 Networking Lunch

13:30 DCVax®: Novel personalised immune therapies for solid tumours

Linda Powers

Linda Powers, CEO, Northwest Biotherapeutics Inc

• DCVax® is a fully personalised precision medicine, tailored to the individual patient and their tumour
• DCVax® mobilizes many active agents of the immune system to hit many targets on the cancer, unlike conventional cancer drugs and some other immune therapies, which generally use a single active agent to hit a single target on the cancer
• Full course of DCVax® doses can be manufactured in a single batch within about a week, and can be stored frozen until needed (including for years).

14:10 Cancer Vaccines: Addressing logistical issues

Eric Leire

Eric Leire, CEO, DanDrit Biotech

• How critical are logistic issues
• How to get your vaccine past phase 3 trials
• Where are the main pitfalls and how to overcome these
 

14:50 Afternoon Tea

15:20 Targeting prostate cancer through peptide based vaccine

Robert Rees

Robert Rees, Director of the Van Geest Cancer Research Centre, Nottingham Trent University

• Considerations of cancer heterogeneity and targeting cancer stem cells
• Epitope identifi cation and the need to target MHC class I and II T-cell responses
• The choice of tumour antigens
• Stratifying patients for immunotherapy and the optimising
vaccine response

16:00 Development of RNA-based vaccines and optimising their efficacy

Mustafa Diken

Mustafa Diken, Deputy Vice President Immunotherapies and Preclinical Research , Biontech RNA Pharmaceuticals GmbH

• Developing RNA vaccines for cancer (RNA and delivery optimization)
• Individualised vaccines against cancer (IVAC)
• Proof of concept (PoC) and mechanism of action studies in
the preclinical setting
• Clinical trial development

16:40 Epitope identification and clinical immune monitoring

Jeremy Fry

Jeremy Fry, Director of Sales, ProImmune Ltd.

• Case studies detailing: Tandem mass spectrometry for T cell epitope identifi cation
• Practical learnings from the use of MHC multimers and ELISPOT in clinical immune monitoring
• Checkpoint blockade immune characterisation assays

17:20 Chairman’s Closing Remarks and Close of Day One

Farzin Farzaneh

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Michael Hanna

Michael Hanna, CEO, Vaccinogen

9:10 The provocative issues of tumor heterogeneity in immunotherapy

Michael Hanna

Michael Hanna, CEO, Vaccinogen

• The biological limitations and reasons for failure of targeted therapeutic approaches for cancer treatment
• You cannot treat a heterogeneous disease with a homogeneous treatment
• The “inside out” approach versus the “outside in” approach to immunotherapy
• The greater benefit of treatment or prevention of occult disease in Immuno-oncology

9:50 The impact of the HPV vaccine in Scotland - a changing landscape

Kevin Pollock

Kevin Pollock, Senior Epidemiologist, Vaccine Preventable Diseases, NHS Greater Glasgow and Clyde

• Uptake of HPV vaccine approximates 90% for all doses in young Scottish women
• Vaccine associated with signifi cant reductions in HPV 16, 18 and other oncogenic types
• Vaccine associated with signifi cant reductions in all grades of cervical intraepithelial neoplasia
• Herd protection vs HPV 16 and 18 in those who are unimmunised

10:30 Morning Coffee

11:00 Omics and big data for cancer vaccines

John Castle

John Castle, Senior Director, Bioinformatics, Agenus

• Immune checkpoint modulators show durable responses in cancer patients
• Omics platforms enable identifi cation of exploitable vaccine targets
• Omics platforms enable identifi cation of patients likely to benefit
• Next step is to combine checkpoint modulators with patient-specifi c vaccines for patient-optimised treatment

11:40 PD-1 Blockade: A broad spectrum anticancer therapeutic

Roy Baynes

Roy Baynes, Senior Vice President Global Clinical Development , Merck Research Laboratories

• Update the development of Pembrolizumab monotherapy across tumor types
• Precision medicine as a key component of optimized immune-oncology therapy
• Development of strategies to address primary resistance and treatment failure

12:20 Networking Lunch

13:30 Irrigating the immune desert: Historical perspective and path forward in GU malignancies

Christina Derleth

Christina Derleth, Medical Director, Genentech, Inc.

• GU Malignancies have become an ideal platform for cancer immunotherapy development
• A minority of patients respond to monotherapy checkpoint inhibition
• Gene expression profi ling of responders and non-responders identifies potential resistance mechanisms
• Personalising immunotherapy is necessary to optimize selection of combination therapy to improve response rates and salvage disease progression

14:10 Case Study: Clinical development of TroVax (MVA-5T4) and identifi cation of biomarkers predictive of response

Richard Harrop

Richard Harrop, Head of Clinical Analysis, Oxford BioMedica (U K) Limited

• Cancer vaccines are believed to have a delayed therapeutic effect, therefore an early marker of effi cacy would be valuable
• Few immunotherapy compounds have demonstrated a clear link between the predicted mode of action of the product and clinical benefit
• Data from a phase III trial of TroVax in renal cancer patients has enabled a detailed investigation of early predictors of treatment benefit and demonstrated that antibodies, induced
by vaccination, against the tumour antigen 5T4 correlated strongly with enhanced patient survival
• We describe the development of a simple biomarker using pre-treatment factors which are readily measured in patients. The biomarker showed a significant correlation with the magnitude of the induced 5T4 antibody response and enhanced survival

14:50 Afternoon Tea

15:20 Development and optimisation of self-adjuvanting protein vaccine

Madiha  Derouazi

Madiha Derouazi, CEO , Amal Therapeutics

• Strengths and weakness of protein vaccines
• Cell penetrating peptides to enhance antigen delivery
and promote MHC class I and II restricted presentation
• TLR peptide agonist as new class of adjuvant

16:00 Activation of anti-regulatory T cells: A novel immuno-oncology approach

Mads Hald Andersen

Mads Hald Andersen, vice-director, professor, co-founder, Center for Cancer Immune Therapy (CCIT), RhoVac, IO Biotech.

• It was remarkable to discover T cells that apparently lacked tolerance to important self-proteins, e.g. IDO, PD-L1 and FoxP3, expressed in regulatory immune cells
• We recently described that these naturally-occurring specific T cells recognize both regulatory immune cells as well as malignant cells
• The ability of self-reactive T cells to react to and eliminate regulatory immune cells can influence general immune reactions
• Epitopes derived from IDO- or PD-L1 are exciting cancer vaccine targets
• It was recently suggested to term these T cells anti-regulatory T cells (anti-Tregs)
• Pro-infl ammatory anti-Tregs that react to regulatory immune cells may enhance local inflammation and inhibit local immune suppression

16:40 IVAC® MUTANOME – A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

Matthias Miller

Matthias Miller, Project Manager, BioNTech AG

• Individualised vaccines against cancer (IVAC®)
• Harnessing mutation-derived neoantigens for the manufacture of RNA-based vaccines for malignant melanoma
• First-in-human clinical trial
• Clinical development of IVAC® MUTANOME

17:20 Chairman’s Closing Remarks and Close of Day Two

Michael Hanna

Michael Hanna, CEO, Vaccinogen

+

FEATURED SPEAKERS

Kevin Pollock

Kevin Pollock

Senior Epidemiologist, Vaccine Preventable Diseases, NHS Greater Glasgow and Clyde
Mustafa Diken

Mustafa Diken

Deputy Vice President Immunotherapies and Preclinical Research , Biontech RNA Pharmaceuticals GmbH

Andrew Gengos

President & CEO, ImmunoCellular Therapeutics Ltd
Andrew Gengos

Campbell Bunce

SVP Scientific Operations, Abzena
Campbell Bunce

Christina Derleth

Medical Director, Genentech, Inc.
Christina Derleth

Eric Leire

CEO, DanDrit Biotech
Eric Leire

Farzin Farzaneh

Professor of Molecular Medicine, Kings College London
Farzin Farzaneh

Jeremy Fry

Director of Sales, ProImmune Ltd.
Jeremy Fry

John Castle

Senior Director, Bioinformatics, Agenus
John Castle

Kevin Pollock

Senior Epidemiologist, Vaccine Preventable Diseases, NHS Greater Glasgow and Clyde
Kevin Pollock

Linda Powers

CEO, Northwest Biotherapeutics Inc
Linda Powers

Madiha Derouazi

CEO , Amal Therapeutics
Madiha  Derouazi

Mads Hald Andersen

vice-director, professor, co-founder, Center for Cancer Immune Therapy (CCIT), RhoVac, IO Biotech.
Mads Hald Andersen

Matthias Miller

Project Manager, BioNTech AG
Matthias Miller

Michael Hanna

CEO, Vaccinogen
Michael Hanna

Mustafa Diken

Deputy Vice President Immunotherapies and Preclinical Research , Biontech RNA Pharmaceuticals GmbH
Mustafa Diken

Richard Harrop

Head of Clinical Analysis, Oxford BioMedica (U K) Limited
Richard Harrop

Robert Rees

Director of the Van Geest Cancer Research Centre, Nottingham Trent University
Robert Rees

Roy Baynes

Senior Vice President Global Clinical Development , Merck Research Laboratories
Roy Baynes

Stephanie Traub

Biomarker Development Specialist at the Centre for Drug Development , Cancer Research UK
Stephanie Traub

Sponsors and Exhibitors

Official Media Partner

Official Publication

Official Online Media Partners

Supporters

Workshops

Cancer vaccines & combination therapies
Workshop

Cancer vaccines & combination therapies

Holiday Inn Kensington Forum
20th September 2016
London, United Kingdom

Active Immune Therapy of Cancer – Emerging Strategies
Workshop

Active Immune Therapy of Cancer – Emerging Strategies

Holiday Inn Kensington Forum
20th September 2016
London, United Kingdom

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Sponsors and Exhibitors


Abzena

Sponsors and Exhibitors
http://www.abzena.com

Abzena offers a suite of complementary services and technologies. Its range of technologies include immunogenicity assessment, antibody drug conjugation, protein engineering, PEGylation, cell line development , GMP manufacturing and a range of bespoke assays to enables the development of better biopharmaceuticals which will have a greater chance of reaching the market.


Northwest Biotherapeutics

Sponsors and Exhibitors
http://www.nwbio.com/

Northwest Biotherapeutics (“NW Bio”) is developing personalized DCVax® dendritic cell-based immunotherapies for both operable and inoperable solid tumors. Unlike conventional cancer drugs and some other immune therapies, which generally use a single active agent to hit a single target on the cancer, DCVax mobilizes many active agents of the immune system to hit many targets on the cancer. NW Bio’s lead product, DCVax-L, is designed to treat all types of operable solid tumors. DCVax-L is currently in a 348-patient international Phase III clinical trial for patients with newly-diagnosed Glioblastoma multiforme brain cancer. Most of the patients have been enrolled, and there is a partial clinical hold in regard to further recruitment. NW Bio’s second product, DCVax-Direct, is designed to treat all types of inoperable solid tumors, through guided intra-tumoral injection anywhere in the body. DCVax-Direct is being evaluated in an ongoing 60-patient Phase I/II trial.

Media Partners


DNAvaccine.com

Official Media Partner
http://www.dnavaccine.com/

The DNA Vaccine Web was launched in 1995 by Robert Whalen. This eventually became DNAvaccine.com and has always been a central resource to the fields of DNA vaccinology and non-viral gene transfer. DNAvaccine.com has helped to teach people about nucleic acid vaccines, find funding opportunities, define collaborative networks, launch new companies, and much more.


Cancer Biomarkers (CBM)

Official Media Partner
http://www.iospress.nl/journal/cancer-biomarkers/

Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.


Journal of Chemotherapy

Official Media Partner
http://www.maneyonline.com/loi/joc

Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research. The Journal publishes original experimental and clinical research articles, reviews, brief communications and letters on all aspects of antimicrobial, anticancer and immunomodulating chemotherapy. Review articles by authoritative experts on new trends and developments in the relevant fields are also invited.


K BioSciences

Official Media Partner
http://kbiosciences.org/

K BioSciences started in 2015 keeping in mind the needs of young aspirants from Bio-Technology and related subjects. Recent discoveries and inventions have made this Biosciences domain more appealing to the ever-growing pool of students, academics, professionals and even to the general public. K BioSciences runs World’s fastest growing Career and Educational Info Portal in the Biosciences domain. We offer you the ability to search through and register for various career opportunities (Ph.D. positions, Postdoc positions, Faculty positions, Scientist positions, Industrial Jobs, and Group Leader) within the domain of Biosciences.

Media Partners


International Journal of Biotechnology

Official Publication
http://www.inderscience.com/ijbt

IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.


International Journal of Bioinformatics Research and Applications

Official Publication
http://www.inderscience.com/ijbra

Bioinformatics is an interdisciplinary research field that combines biology, computer science, mathematics and statistics into a broad-based field that will have profound impacts on all fields of biology. The emphasis of IJBRA is on basic bioinformatics research methods, tool development, performance evaluation and their applications in biology. IJBRA addresses the most innovative developments, research issues and solutions in bioinformatics and computational biology and their applications.

Media Partners


The Pharma Letter

Official Online Media Partners
http://www.thepharmaletter.com/

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.

Media Partners


Pharmalicensing

Supporters
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


American Pharmaceutical Review

Supporters
http://www.americanpharmaceuticalreview.com

American Pharmaceutical Review is the leading review of business and technology for the pharmaceutical industry throughout North America. Each issue offers unbiased editorial on drug delivery, information technology, research & development, analytical development and control, equipment and facility manufacturing and regulatory affairs. American Pharmaceutical keeps its 30,000 readers including senior executives, technical personnel, scientists, and others fully abreast of the latest trends and developments in the process of pharmaceutical manufacturing.


EBR

Supporters
http://www.samedanltd.com

European BioPharmaceutical Review (EBR) provides a dedicated platform of communication and information for the biopharmaceutical market across Europe, North America and the rest of the world. Each quarterly issue, 10,500 copies of the magazine are distributed to our specially-targeted readership with articles on the hottest topics written by eminent commentators from the biotech scene. www.samedanltd.com


Pharmiweb

Supporters
http://www.pharmiweb.com

Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


Gate2Biotech

Supporters
http://www.gate2biotech.com

Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


Drug Development Technology

Supporters
http://www.drugdevelopment-technology.com

Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


Technology Networks

Supporters
http://www.technologynetworks.com

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Drug Discovery Today

Supporters
http://www.drugdiscoverytoday.com/

Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


Swiss Biotech Association

Supporters
http://www.swissbiotech.org/

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


Labsave

Supporters
http://www.labsave.com

Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


CanBiotech

Supporters
http://www.canbiotech.com

CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


Pharmaceutical Technology

Supporters
http://www.pharmaceutical-technology.com

Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


Absave

Supporters
http://www.absave.com

Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


Drug Target Review

Supporters
http://www.drugtargetreview.com

Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


Medical News Today

Supporters
http://www.medicalnewstoday.com

Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.


Bentham Science

Supporters
http://www.benthamscience.com/

Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


Inderscience Publishers

Supporters
http://www.inderscience.com

Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


Pharmavision

Supporters
http://www.pharmavision.co.uk

PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


IOS Press

Supporters
http://www.iospress.nl

IOS Press publishes about 120 new books and 100 international journals each year covering topics ranging from computer science and mathematics to medicine and the natural sciences. All titles in this catalogue are available online as well as in print. Many titles are covered in the most important abstracting databases, such as Thomson Reuters / ISI, MEDLINE and SciVerse Scopus. Headquartered in Amsterdam with satellite offices in the USA, Germany, India and China, IOS Press has established several strategic co-publishing initiatives. Notable acquisitions included Delft University Press in 2005 and Millpress Science Publishers in 2008. IOS Press journals are available through the highly-regarded MetaPress platform.


Biosave

Supporters
http://www.Biosave.com

Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


GBI

Supporters
http://www.gbihealth.com/

GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


BioPharm Insight

Supporters
http://www.infinata.com/biopharma-solution/by-product/biopharm-insight.html

BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.


Pharmacircle

Supporters
http://www.pharmacircle.com

PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


Pharmaceutical Outsourcing

Supporters
http://www.pharmoutsourcing.com

Pharmaceutical Outsourcing, the journal dedicated to pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry to our 15,000 readers in North America.


One Nucleus

Supporters
http://www.onenucleus.com

Established in May 2010, One Nucleus is the result of the merger of ERBI and London Biotechnology Network. One Nucleus is a not-for-profit membership organisation for international life science and healthcare companies and the largest of its kind in Europe. The company is based in Cambridge UK and London, at the heart of Europe's largest cluster. The 470 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial Service Providers.


SelectScience

Supporters
http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


Taylor & Francis Group

Supporters
http://bit.ly/TF-Med

As one of the world’s leading publishers of scholarly journals, books, eBooks, reference works, and databases, Taylor & Francis Group partners with researchers, scholarly societies, universities, and libraries worldwide to bring knowledge to life.


PharmaVOICE

Supporters
http://www.pharmavoice.com

PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


Labhoo

Supporters
http://www.labhoo.com



Farmavita

Supporters
http://www.farmavita.net/

Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


Thomson Reuters

Supporters
http://thomsonreuters.com/products_services/science/

Thomson Reuters is the leading source of intelligent information for professionals around the world. We provide essential information to keep you in touch with the rapidly-changing pharmaceutical and chemical markets, expert services to help you make informed, early decisions, and intuitive technology to manage and support your discovery and development activities. Our products give you the intelligence, tools and expertise to help you optimize your IP portfolio, monitor industry developments, identify licensing and partnering opportunities, deliver successful regulatory submissions, and support your scientific messaging, marketing, product positioning, and awareness campaigns.


Samedan

Supporters
http://www.samedanltd.com/magazine/13.

International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.


Biocompare

Supporters
http://www.biocompare.com

Biocompare is the most comprehensive, in-depth, and objective website for life science product information. Thousands of scientists use Biocompare daily to quickly find the right product for their experiments rather than looking through multiple print catalogs. Visit Biocompare to find the products you need, stay informed of new technologies, read product reviews, watch product videos, and keep up-to-date on life science news. Visit: www.biocompare.com

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, United Kingdom, Link to Map
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.